CJ CheilJedang reported second quarter 2026 earnings driven by strong US market growth in GSP categories like mandu and hapan, particularly through Costco channels, while its bio business faces headwinds from intensifying competition in China and price declines in products such as tryptophan. The company expects US tariffs on Chinese lysine to improve market conditions and support amino acid price recovery, with final tariffs implemented in September and benefits more visible in the fourth quarter. Technical solutions, which accounts for about 10% of total sales excluding logistics, is positioned as a long-term growth driver through high-value products like taste and nutrition, PHA, and health and wellness. Net debt increased by KRW800 billion due to FX rate hikes, seasonal working capital needs, and CapEx investments, but is expected to normalize by year-end. The company maintained its 2026 CapEx forecast of KRW1.1 trillion, with 60% to 70% allocated to new projects, primarily the new lifestyle foods business.
CJ CheiljedangStrong US growth in GSP categories like mandu and hapan, particularly through Costco, drives earnings.
Costco Wholesale Corp
